We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Par Files Declaratory Suit Over Diabetes Generic

Law360 (April 16, 2009, 12:00 AM EDT) -- Novartis AG and Japanese drugmaker Ajinomoto Co. Inc. have been hit with a declaratory action by Par Pharmaceutical Inc., which is looking to market a generic version of the companies’ type 2 diabetes drug Starlix.

Par filed the complaint Wednesday in the U.S. District Court for the Eastern District of Pennsylvania, asking for a declaratory judgment that it will not infringe the six patents owned by Novartis and Ajinomoto related to Starlix.

Novartis currently holds a new drug application for 60 mg and 120 mg oral...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.